MERSANA THERAPEUTICS INC (MRSN) Stock Price & Overview
NASDAQ:MRSN • US59045L2051
Current stock price
The current stock price of MRSN is 29.08 USD. Today MRSN is up by 0.14%. In the past month the price increased by 5.86%. In the past year, price increased by 61.56%.
MRSN Key Statistics
- Market Cap
- 145.4M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -13.88
- Dividend Yield
- N/A
MRSN Stock Performance
MRSN Stock Chart
MRSN Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to MRSN. When comparing the yearly performance of all stocks, MRSN is one of the better performing stocks in the market, outperforming 98.16% of all stocks.
MRSN Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to MRSN. Both the profitability and financial health of MRSN have multiple concerns.
MRSN Earnings
On November 14, 2025 MRSN reported an EPS of -1.51 and a revenue of 11.01M. The company beat EPS expectations (8.12% surprise) and missed revenue expectations (-23.98% surprise).
MRSN Forecast & Estimates
14 analysts have analysed MRSN and the average price target is 51 USD. This implies a price increase of 75.38% is expected in the next year compared to the current price of 29.08.
For the next year, analysts expect an EPS growth of 39.26% and a revenue growth -24.85% for MRSN
MRSN Groups
Sector & Classification
MRSN Financial Highlights
Over the last trailing twelve months MRSN reported a non-GAAP Earnings per Share(EPS) of -13.88. The EPS increased by 8.98% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -111.8% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
MRSN Ownership
MRSN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.4 | 351.47B | ||
| AMGN | AMGEN INC | 15.09 | 185.95B | ||
| GILD | GILEAD SCIENCES INC | 14.75 | 161.855B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.09 | 109.449B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.03 | 79.456B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.76 | 40.768B | ||
| INSM | INSMED INC | N/A | 29.176B | ||
| NTRA | NATERA INC | N/A | 28.878B | ||
| BIIB | BIOGEN INC | 11.44 | 27.06B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 26.812B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.41 | 24.859B | ||
| MRNA | MODERNA INC | N/A | 20.119B | ||
| INCY | INCYTE CORP | 12.23 | 18.836B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MRSN
Company Profile
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of antibody-drug conjugates that offer clinical benefit for cancer patients. The company is headquartered in Cambridge, Massachusetts and currently employs 102 full-time employees. The company went IPO on 2017-06-28. The firm also focuses on adult oncology. Its pipeline includes tovorafenib (OJEMDA), DAY301, emiltatug ledadotin (Emi-Le), a novel antibody drug conjugate (ADC) targeting the B7-H4 protein in clinical development to treat the rare cancer adenoid cystic carcinoma (ACC). The company has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is a cytotoxic ADC platform that is designed to generate site-specific, homogeneous ADCs. Immunosynthen is its proprietary stimulator of interferon genes (STING)-agonist platform that is designed to generate systemically administered ADCs that locally activate STING signaling in both antigen-expressing tumor cells and in tumor-resident immune cells.
Company Info
IPO: 2017-06-28
MERSANA THERAPEUTICS INC
840 Memorial Drive
Cambridge MASSACHUSETTS 02139 US
CEO: Anna Protopapas
Employees: 102
Phone: 16174980020
MERSANA THERAPEUTICS INC / MRSN FAQ
What does MRSN do?
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of antibody-drug conjugates that offer clinical benefit for cancer patients. The company is headquartered in Cambridge, Massachusetts and currently employs 102 full-time employees. The company went IPO on 2017-06-28. The firm also focuses on adult oncology. Its pipeline includes tovorafenib (OJEMDA), DAY301, emiltatug ledadotin (Emi-Le), a novel antibody drug conjugate (ADC) targeting the B7-H4 protein in clinical development to treat the rare cancer adenoid cystic carcinoma (ACC). The company has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is a cytotoxic ADC platform that is designed to generate site-specific, homogeneous ADCs. Immunosynthen is its proprietary stimulator of interferon genes (STING)-agonist platform that is designed to generate systemically administered ADCs that locally activate STING signaling in both antigen-expressing tumor cells and in tumor-resident immune cells.
What is the current price of MRSN stock?
The current stock price of MRSN is 29.08 USD. The price increased by 0.14% in the last trading session.
What is the dividend status of MERSANA THERAPEUTICS INC?
MRSN does not pay a dividend.
How is the ChartMill rating for MERSANA THERAPEUTICS INC?
MRSN has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Is MERSANA THERAPEUTICS INC (MRSN) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on MRSN.
Can you provide the growth outlook for MERSANA THERAPEUTICS INC?
The Revenue of MERSANA THERAPEUTICS INC (MRSN) is expected to decline by -24.85% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
When does MERSANA THERAPEUTICS INC (MRSN) report earnings?
MERSANA THERAPEUTICS INC (MRSN) will report earnings on 2026-03-02, after the market close.